Showing results (381-390 of 420) with videos related to

Sort By:
Pageof 42
Journal of Clinical Pharmacology|August 1, 1981
Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicinC E Riggs, M J Egorin, J Z Fuks, et al.
The American Journal of Medicine|April 1, 1979
Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin or netilmicin in febrile patients with granulocytopenia and cancerL J Love, S C Schimpff, D M Hahn, et al.
Leukemia & Lymphoma|July 1, 1994
Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimenJ A Sparano, P H Wiernik, M Strack, et al.
Journal of Pain and Symptom Management|August 1, 1991
Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomitingM Lane, C L Vogel, J Ferguson, et al.
Archives of Neurology|September 1, 1987
Quantitative sensory testing demonstrates that subclinical sensory neuropathy is prevalent in patients with cancerR B Lipton, B S Galer, J P Dutcher, et al.
Cancer Investigation|January 1, 1992
Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology GroupP H Wiernik, B Yeap, S E Vogl, et al.
Journal of the National Cancer Institute|July 18, 1990
High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinomaJ S Abrams, A A Rayner, P H Wiernik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1996
Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphomaJ A Sparano, P H Wiernik, X Hu, et al.
The American Journal of Clinical Nutrition|December 1, 1991
Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cellsS L Marcus, D P Petrylak, J P Dutcher, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1982
Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patientsR S Finley, C L Fortner, C A deJongh, et al.
Pageof 42